Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
20,427,086
-
Share change
-
+1,924,855
-
Total reported value
-
$208,559,142
-
Put/Call ratio
-
153%
-
Price per share
-
$10.21
-
Number of holders
-
72
-
Value change
-
+$16,523,370
-
Number of buys
-
54
-
Number of sells
-
14
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2018
As of 30 Jun 2018,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,427,086 shares.
The largest 10 holders included
FMR LLC, Flagship Pioneering Inc., ARK Investment Management LLC, Redmile Group, LLC, BlackRock Inc., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, MILLENNIUM MANAGEMENT LLC, and JPMORGAN CHASE & CO.
This page lists
72
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.